Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Preeclampsia
Interventions: Recombinant human antithrombin (ATryn), Normal Saline 0.9%; Biological · Other
Lead sponsor: rEVO Biologics; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more

Conditions: Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions: Dociparstat sodium, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more

Conditions: Postpartum Hemorrhage
Interventions: Tranexamic Acid, Placebo; Normal Saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dysplasia, Congenital Hip
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Anesthesia
Interventions: IV Methylphenidate, Propofol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative
Interventions: Liposomal bupivacaine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Hyperoxaluria
Interventions: DCR-PHXC, Placebo; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 6 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Socioemotional Aging
Interventions: Oxytocin Spray, Placebo Spray; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA-BN-RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 55 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Redding, California • San Diego, California • The Villages, Florida + 9 more

Conditions: Healthy
Interventions: HF1K16, Placebo; Drug
Lead sponsor: HighField Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Age Related Cataracts
Interventions: EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%, Saline Solution (Placebo); Drug
Lead sponsor: Livionex Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more

Conditions: Obesity
Interventions: intravenous acetaminophen, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia
Interventions: transcranial Direct Current Stimulation (tDCS), Sham, Cognitive Assessment, Brain Games Stimulation; Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Invasive Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Lung Transplant
Interventions: Tocilizumab, Placebo for Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: Cancer of the Bone, Limb Salvage
Interventions: Tranexamic Acid, 0.9% sodium chloride; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 24 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
Interventions: Lidocaine, Amiodarone, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions: Triamcinolone Acetonide Injectable Suspension, Saline injection; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Sepsis, Severe, Septic Shock
Interventions: Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lakewood, New Jersey • Toms River, New Jersey

Conditions: Osteoarthritis, Knee
Interventions: XT-150, Placebo; Biological · Drug
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: La Mesa, California • Napa, California • Santa Monica, California + 1 more

Conditions: Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Interventions: Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infertility of Uterine Origin
Interventions: Platelet Rich Plasma Intrauterine infusion, Normal saline Intrauterine infusion; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions: Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Tranexamic Acid and Thromboelastography During Cesarean Delivery

Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

Faces: Choices Study

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract

Prospective, Double Blind, Placebo Control, Bariatric IV Ace

Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Tocilizumab in Lung Transplantation

Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure

Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Platelet Rich Plasma for Insufficient Endometrium

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy